Generics Industry Hungry For More After Showing Larger GLP-1 Appetite In 2024

Sandoz, Viatris Look To Be In Commercial Vanguard; Supply Core, CDMOs Vital

GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.

Generics producers are keen for a piece of the GLP-1 pie

With the addition of weight loss and obesity indications and more patient-friendly dosing regimens beginning at the start of the current decade, glucagon-like-peptide-1 (GLP-1) receptor agonists have exploded into a multi-billion-dollar, cultural phenomenon, comparable in the prescription pharma space to the arrival of Viagra (sildenafil) in the late 1990s or Botox (onabotulinumtoxinA) before it.

The global market for such products has been tipped to reach $71bn by 2032, or even as high as $100bn...

More from Strategy

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By 

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By 

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership

 
• By 

Ahead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.

Xbrane Sets Date For Latest Run At Ranibizumab In US

 
• By 

After a series of setbacks for its Lucentis (ranibizumab) biosimilar filing in the US, Xbrane Biopharma now has a fresh action date from the FDA – although any approval will be contingent on a successful agency reinspection of its manufacturing sites.

More from Generics Bulletin Perspectives

Biosimilar Year In Review: Regulatory Achievements And Future Aspirations

 

This year, regulators questioned the US interchangeability designation and the need for comparative efficacy trials, while finding ways to promote biosimilar development and accessibility. Will this momentum continue in 2025? Generics Bulletin spoke to experts from across the industry to hear their views.

The Generics Bulletin Podcast: Highlights Of 2024

 
• By 

Generics Bulletin's editorial team discusses key topics from the year, including the latest rankings of the Generics Bulletin Top 50, Amgen’s surprise launch of a US Eylea biosimilar, the EU’s Urban Waste Water Treatment Directive and supply-chain issues for the off-patent sector.

October Surprise: How Amgen’s Aflibercept Launch Shook Up US Biosimilars In 2024

 
• By 

As the US biosimilars market approaches the end of its first decade, it has seen another busy year, with Amgen’s surprise launch of a rival to Eylea shaking up expectations as other first-time approvals rolled in throughout 2024.